WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010024676) DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/024676    International Application No.:    PCT/NL2009/050518
Publication Date: 04.03.2010 International Filing Date: 31.08.2009
IPC:
A61K 39/395 (2006.01), A61K 38/00 (2006.01), A61K 31/00 (2006.01), A61P 35/00 (2006.01), A61P 31/00 (2006.01)
Applicants: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC [NL/NL]; Albinusdreef 2 NL-2333 ZA Leiden (NL) (For All Designated States Except US).
Herbert-Fransen, Marieke Fernande [NL/NL]; (NL) (For US Only).
Melief, Cornelis Joseph Maria [NL/NL]; (NL) (For US Only)
Inventors: Herbert-Fransen, Marieke Fernande; (NL).
Melief, Cornelis Joseph Maria; (NL)
Agent: VAN WESTENBRUGGE, Andre; (NL)
Priority Data:
08163311.7 29.08.2008 EP
61/092,792 29.08.2008 US
Title (EN) DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT
(FR) ADMINISTRATION D’UN AGONISTE DE CD40 À UN GANGLION LYMPHATIQUE DRAINANT UNE TUMEUR D’UN SUJET
Abstract: front page image
(EN)The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease,wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph nodeof a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered.
(FR)La présente invention concerne l’utilisation d’un agoniste de CD40 pour traiter un cancer, un trouble prémalin ou une maladie infectieuse, où un agoniste de CD40 est administré localement et ciblé sur un ganglion lymphatique drainant une tumeur d’un sujet. Éventuellement, un agoniste de CD40 est formulé dans une formulation à libération lente. Éventuellement, un peptide activant CTL est également administré.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)